DOCSLIB.ORG

Identification of Novel Biomarker Candidates for Hypertrophic Cardiomyopathy and Other Cardiovascular Diseases Leading to Heart Failure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification of Novel Biomarker Candidates for Hypertrophic Cardiomyopathy and Other Cardiovascular Diseases Leading to Heart Failure Physiol. Res. 65: 751-762, 2016 https://doi.org/10.33549/physiolres.933253 Identification of Novel Biomarker Candidates for Hypertrophic Cardiomyopathy and Other Cardiovascular Diseases Leading to Heart Failure H. REHULKOVA1, P. REHULKA1, A. MYSLIVCOVA FUCIKOVA1, J. STULIK1, R. PUDIL2 1Department of Molecular Pathology and Biology, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic, 21st Department of Internal Medicine – Cardioangiology, Faculty Hospital, Hradec Kralove, Czech Republic Received November 9, 2015 Accepted April 8, 2016 On-line July 15, 2016 Summary Introduction In-depth proteome discovery analysis represents new strategy in an effort to identify novel reliable specific protein markers for Heart failure (HF) is not a uniform syndrome. It hypertrophic cardiomyopathy and other life threatening encompasses various causes as cardiomyopathy, cardiovascular diseases. To systematically identify novel protein congenital heart diseases, hypertension and ischemic biomarkers of cardiovascular diseases with high mortality we heart disease. The molecular basis of this entity is not employed an isobaric tag for relative and absolute quantitation completely understood (Yang et al. 2015). Hypertrophic (iTRAQ) proteome technology to make comparative analysis of cardiomyopathy (HCM), one of the pathologies plasma samples obtained from patients suffering from non- contributing to HF, has been defined morphologically by obstructive hypertrophic cardiomyopathy, stable dilated unexplained hypertrophy in the absence of cardiomyopathy, aortic valve stenosis, chronic stable coronary haemodynamic stress, and at the histological level by artery disease and stable arterial hypertension. We found myocyte disarray, fibrosis, and abnormalities of the 128 plasma proteins whose abundances were uniquely regulated intramyocardial small vessels. HCM is a monogenic among the analyzed cardiovascular pathologies. 49 of them have cardiac disease with an autosomal dominant pattern of not been described yet. Additionally, application of statistical heritability and with prevalence in the general population exploratory analyses of the measured protein profiles indicated of 1/500. More than 1,400 different mutations have been the relationship in pathophysiology of the examined discovered so far, involving mutations in 11 genes of cardiovascular pathologies. contractile sarcomeric proteins that have been shown to produce the disease (Hensley et al. 2015). Asymmetrical Key words septal hypertrophy leads to a significant pressure gradient Cardiovascular diseases • Biomarkers • Proteome analysis • between the apical left ventricular (LV) chamber and the Statistical evaluation left ventricular outflow tract (LVOT), resulting in the so- called ‘hypertrophic obstructive cardiomyopathy’ Corresponding author (obstructive HCM) presentation (Hensley et al. 2015). J. Stulik, Department of Molecular Pathology and Biology, Faculty The prevalence of LVOT obstruction in HCM is 20-30 % of Military Health Sciences, University of Defence, at rest and up to 70 % with provocation (Cooper et al. Trebesska 1575, 500 01 Hradec Kralove, Czech Republic. E-mail: 2015). Majority of patients with obstructive HCM are [email protected] asymptomatic but some can present with heart failure or arrhythmias. Just arrhythmias, premature sudden cardiac PHYSIOLOGICAL RESEARCH • ISSN 0862-8408 (print) • ISSN 1802-9973 (online) 2016 Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic Fax +420 241 062 164, e-mail: [email protected], www.biomed.cas.cz/physiolres 752 Rehulkova et al. Vol. 65 deaths, heart failure and less frequently thromboembolic recommendations (Lang et al. 2015). The term “stable” events are primary causes of mortality amongst HCM means that patient is clinically stable at least for one patients (Kumar et al. 2015). Ultimately, about 10 % of month before the enrollment to the study. obstructive HCM patients progress to an end-stage dilated Patients were enrolled into the study phase with LV wall thinning, cavity enlargement, and consecutively. There was no selection bias according to systolic dysfunction that resembles a dilated age, gender and medication. However, the patients with cardiomyopathy (DCM) (Xiao et al. 2015). significant concomitant disease, such as pulmonary The classification of heart failure is traditionally disease, malignancy, autoimmune disorders, neurodege- based on the pathological cause of failure of the cardiac nerative disorders, thyroid disease, or concurrent viral pump, the pathophysiological characteristics, and the disease were excluded. Baseline characteristics of the acuity and severity of the heart failure. There is general population of this study are shown in Table 1. assumption that identification of biomarker profiles of Results were compared to control group of pathologies threatening by heart failure can provide healthy 46 blood donors aged 55 to 67 years (median age additional criteria for risk stratification among HF 60 years) with no evidence of cardiovascular disease or patients (Braunwald 2008). From this point of view other severe disorders. Statistical analysis of the age plasma is very useful clinical specimen for the differences showed no significant differences between all identification of novel markers of cardiovascular studied groups with one exception of aortic stenosis. diseases. Some plasma proteins like proteins of There the median of age was significantly higher than in coagulation cascade, proteins of lipid transfer, proteins the other groups, because of the higher prevalence of interacting with vessel walls or platelets and, finally, degenerative etiology aortic stenosis. inflammatory proteins were found to be directly involved The study protocol conformed to the ethical pathogenesis of the cardiovascular system (Anderson guidelines of the 1975 Declaration of Helsinki, and was 2005). Plasma also represents the largest proteome of the approved by the ethical committee of our institution. human body exhibiting extremely dynamic ranges in Informed consent was obtained from each patient. protein concentration. This makes its quantitative analysis highly challenging. Nevertheless, current advanced mass Plasma sample collection spectrometry approaches preceded with different pre- Blood samples (before echocardiography and fractionation techniques enable to quantitate several cardiac catheterization) were obtained from left forearm thousand plasma proteins in one run (Keshishian et al. after an overnight fasting at the First Department of 2015). Internal Medicine of the University Hospital in Hradec In our study we employed isobaric tag for Kralove. The control samples were obtained from healthy relative and absolute quantitation (iTRAQ) technology donors at the Transfusion Department of the same labeling of peptides (Wiese et al. 2007) for comparison of hospital. The BD P100v1.1 vacuum tubes containing plasma protein profiles of patients with HCM and other protease inhibitors and EDTA anticoagulant were used diseases of the cardiovascular system, which are (Becton Dickinson, Franklin Lakes, NJ). Within one accompanied with structural changes of the myocardium hour, the blood samples were centrifuged for 20 min at and can lead to its failure. 2500 g at 22 °C and the supernatant was removed, aliquoted and kept at -80 °C until a further analysis was Methods performed. Study population Plasma immunoaffinity enrichment Study population consisted of five groups: An equal volume was taken from each patient patients with non-obstructive HCM, patients with aortic sample to create pooled aliquots of each group, all in valve stenosis (AS), chronic stable coronary artery duplicate. These pooled aliquots were depleted from disease (CAD), stable arterial hypertension (AH), and fourteen most abundant plasma proteins (albumin, IgG, stable DCM. The diagnosis of HCM was based on antitrypsin, IgA, transferrin, haptoglobin, fibrinogen, a history of illness, physical examination, alpha-2-macroglobulin, alpha-1-acid glycoprotein, IgM, echocardiography, and cardiac catheterization in apolipoprotein A1, apolipoprotein A2, complement C3, accordance with European Society of Cardiology and transthyretin) using HPLC immunoaffinity column 2016 Identification of Novel Biomarkers in Cardiovascular Diseases 753 MARS Hu-14 (Multiple Affinity Removal System of plasma proteins were then concentrated and desalted Agilent Technologies, Santa Clara, CA) according to using 3K Amicon Ultra centrifugal filter units (Millipore manufacturer´s instructions. Obtained depleted fractions Corporation, Bedford, MA). Table 1. Baseline characteristics of patients groups in the study. HCM DCM CAD AS AH (n=47) (n=21) (n=20) (n=24) (n=20) Age (years) 58.4±12.4 57.6±12.0 62.8±9.2 70.6±11.6 54.7±15.8 Female gender, n (%) 12 (26) 4 (19) 3 (15) 6 (25) 7 (35) NYHA functional class, n (%) I 21 (45) 4 (19) 13 (65) 3 (13) 20 (100) II 18 (38) 14 (67) 5 (25) 15 (63) 0 III-IV 8 (17) 3 (14) 2 (10) 6 (25) 0 Atrial fibrillation, n (%) 14 (30) 6 (29) 3 (15) 6 (25) 2 (10) Creatinine level (μmol.l-1) 94.0±29.8 88.3±18.0 89.7±29.0 109.9±44.7 91.7±18.9 Diabetes mellitus, n (%) 13 (28) 4 (19) 4 (20) 9 (38) 4 (20) Hyperlipidemia, n (%) 23 (49) 9 (43) 19 (95) 15 (63) 13 (65) Smoking, n (%) 20 (43) 12 (57) 15 (75) 9 (38) 9 (45) Echocardiography LA (mm) 48.2±7.2 42.1±12.3 43.1±7.4 44.0±6.0 42.7±2.9 RV (mm) 26.1±3.8 26.5±7.7 26.8±2.8 26.7±3.4 27.2±2.4 IVST (mm) 19.4±4.4 10.4±2.6 11.3±1.9 13.9±2.1 12.1±1.3 LV ESD (mm) 31.9±7.1
Load more

Recommended publications
  • Supplementary Table 3 Complete List of RNA-Sequencing Analysis of Gene Expression Changed by ≥ Tenfold Between Xenograft and Cells Cultured in 10%O2
    Supplementary Table 3 Complete list of RNA-Sequencing analysis of gene expression changed by ≥ tenfold between xenograft and cells cultured in 10%O2 Expr Log2 Ratio Symbol Entrez Gene Name (culture/xenograft) -7.182 PGM5 phosphoglucomutase 5 -6.883 GPBAR1 G protein-coupled bile acid receptor 1 -6.683 CPVL carboxypeptidase, vitellogenic like -6.398 MTMR9LP myotubularin related protein 9-like, pseudogene -6.131 SCN7A sodium voltage-gated channel alpha subunit 7 -6.115 POPDC2 popeye domain containing 2 -6.014 LGI1 leucine rich glioma inactivated 1 -5.86 SCN1A sodium voltage-gated channel alpha subunit 1 -5.713 C6 complement C6 -5.365 ANGPTL1 angiopoietin like 1 -5.327 TNN tenascin N -5.228 DHRS2 dehydrogenase/reductase 2 leucine rich repeat and fibronectin type III domain -5.115 LRFN2 containing 2 -5.076 FOXO6 forkhead box O6 -5.035 ETNPPL ethanolamine-phosphate phospho-lyase -4.993 MYO15A myosin XVA -4.972 IGF1 insulin like growth factor 1 -4.956 DLG2 discs large MAGUK scaffold protein 2 -4.86 SCML4 sex comb on midleg like 4 (Drosophila) Src homology 2 domain containing transforming -4.816 SHD protein D -4.764 PLP1 proteolipid protein 1 -4.764 TSPAN32 tetraspanin 32 -4.713 N4BP3 NEDD4 binding protein 3 -4.705 MYOC myocilin -4.646 CLEC3B C-type lectin domain family 3 member B -4.646 C7 complement C7 -4.62 TGM2 transglutaminase 2 -4.562 COL9A1 collagen type IX alpha 1 chain -4.55 SOSTDC1 sclerostin domain containing 1 -4.55 OGN osteoglycin -4.505 DAPL1 death associated protein like 1 -4.491 C10orf105 chromosome 10 open reading frame 105 -4.491
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Biological Models of Colorectal Cancer Metastasis and Tumor Suppression
    BIOLOGICAL MODELS OF COLORECTAL CANCER METASTASIS AND TUMOR SUPPRESSION PROVIDE MECHANISTIC INSIGHTS TO GUIDE PERSONALIZED CARE OF THE COLORECTAL CANCER PATIENT By Jesse Joshua Smith Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University In partial fulfillment of the requirements For the degree of DOCTOR OF PHILOSOPHY In Cell and Developmental Biology May, 2010 Nashville, Tennessee Approved: Professor R. Daniel Beauchamp Professor Robert J. Coffey Professor Mark deCaestecker Professor Ethan Lee Professor Steven K. Hanks Copyright 2010 by Jesse Joshua Smith All Rights Reserved To my grandparents, Gladys and A.L. Lyth and Juanda Ruth and J.E. Smith, fully supportive and never in doubt. To my amazing and enduring parents, Rebecca Lyth and Jesse E. Smith, Jr., always there for me. .my sure foundation. To Jeannine, Bill and Reagan for encouragement, patience, love, trust and a solid backing. To Granny George and Shawn for loving support and care. And To my beautiful wife, Kelly, My heart, soul and great love, Infinitely supportive, patient and graceful. ii ACKNOWLEDGEMENTS This work would not have been possible without the financial support of the Vanderbilt Medical Scientist Training Program through the Clinical and Translational Science Award (Clinical Investigator Track), the Society of University Surgeons-Ethicon Scholarship Fund and the Surgical Oncology T32 grant and the Vanderbilt Medical Center Section of Surgical Sciences and the Department of Surgical Oncology. I am especially indebted to Drs. R. Daniel Beauchamp, Chairman of the Section of Surgical Sciences, Dr. James R. Goldenring, Vice Chairman of Research of the Department of Surgery, Dr. Naji N.
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
    [Show full text]
  • Supplementary Table 1. the List of Proteins with at Least 2 Unique
    Supplementary table 1. The list of proteins with at least 2 unique peptides identified in 3D cultured keratinocytes exposed to UVA (30 J/cm2) or UVB irradiation (60 mJ/cm2) and treated with treated with rutin [25 µM] or/and ascorbic acid [100 µM]. Nr Accession Description 1 A0A024QZN4 Vinculin 2 A0A024QZN9 Voltage-dependent anion channel 2 3 A0A024QZV0 HCG1811539 4 A0A024QZX3 Serpin peptidase inhibitor 5 A0A024QZZ7 Histone H2B 6 A0A024R1A3 Ubiquitin-activating enzyme E1 7 A0A024R1K7 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein 8 A0A024R280 Phosphoserine aminotransferase 1 9 A0A024R2Q4 Ribosomal protein L15 10 A0A024R321 Filamin B 11 A0A024R382 CNDP dipeptidase 2 12 A0A024R3V9 HCG37498 13 A0A024R3X7 Heat shock 10kDa protein 1 (Chaperonin 10) 14 A0A024R408 Actin related protein 2/3 complex, subunit 2, 15 A0A024R4U3 Tubulin tyrosine ligase-like family 16 A0A024R592 Glucosidase 17 A0A024R5Z8 RAB11A, member RAS oncogene family 18 A0A024R652 Methylenetetrahydrofolate dehydrogenase 19 A0A024R6C9 Dihydrolipoamide S-succinyltransferase 20 A0A024R6D4 Enhancer of rudimentary homolog 21 A0A024R7F7 Transportin 2 22 A0A024R7T3 Heterogeneous nuclear ribonucleoprotein F 23 A0A024R814 Ribosomal protein L7 24 A0A024R872 Chromosome 9 open reading frame 88 25 A0A024R895 SET translocation 26 A0A024R8W0 DEAD (Asp-Glu-Ala-Asp) box polypeptide 48 27 A0A024R9E2 Poly(A) binding protein, cytoplasmic 1 28 A0A024RA28 Heterogeneous nuclear ribonucleoprotein A2/B1 29 A0A024RA52 Proteasome subunit alpha 30 A0A024RAE4 Cell division cycle 42 31
    [Show full text]
  • Usbiological Datasheet
    Cytosol Nonspecific Dipeptidase 2, Recombinant, Human (CNDP2, CPGL, Glutamate Carboxypeptidase- Like Protein 1, Peptidase A, Tissue Carnosinase) Catalog number C9090-50 Supplier United States Biological The human CNDP2 gene encodes cytosol nonspecific dipeptidase, a member of the M20 family of metalloproteases (2, 3). Also known as glutamate carboxypeptidase-like protein 1 (CPGL), tissue carnosinase or peptidase A, CNDP2 is ubiquitously expressed throughout human tissues. Unlike CNDP1, CNDP2 has broad substrate specificity for dipeptides with free amino and carboxyl groups. Source Recombinant human cytosolic nonspecific dipeptidase encoded by the CNDP2 gene (human CNDP2, residue 1-475; Accession# Q96KP4) (1,2) was expressed with a C-terminal 10X His tag in Sf21 insect cells. Molecular Mass The purified rhCNDP2 migrates as three bands in SDS-PAGE with molecular masses of approximately 54, 38 and 22 kD. The 54 kD band corresponds to the full-length protein (485 amino acids). The 38 and 22 kD bands correspond to the N- and C-terminal fragments, respectively. The N-terminal sequencing of rhCNDP2 revealed only S 299HKKDILMHR, which corresponds to the N-terminus of the 22kD fragment. Endotoxin Level < 1.0 EU per 1 μg of the protein as determined by the LAL method. Activity Measure by its ability to cleave carnosine (β-Ala-His) in a two-step assay. See Activity Assay protocol on next page for details. The specific activity, as measured using the procedure above, is > 70 pmoles/min/μg. Storage Samples are stable for up to six months at -70° C in a manual defrost freezer after the receipt. After receiving, this enzyme can be aliquoted and stored under the above temperature for six months without a significant loss of activity.
    [Show full text]
  • Electronic Supplementary Material (ESI) for Analyst. This Journal Is © the Royal Society of Chemistry 2020
    Electronic Supplementary Material (ESI) for Analyst. This journal is © The Royal Society of Chemistry 2020 Table S1.
    [Show full text]
  • Protein Symbol Protein Name Rank Metric Score 4F2 4F2 Cell-Surface
    Supplementary Table 2 Supplementary Table 2. Ranked list of proteins present in anti-Sema4D treated macrophage conditioned media obtained in the GSEA analysis of the proteomic data. Proteins are listed according to their rank metric score, which is the score used to position the gene in the ranked list of genes of the GSEA. Values are obtained from comparing Sema4D treated RAW conditioned media versus REST, which includes untreated, IgG treated and anti-Sema4D added RAW conditioned media. GSEA analysis was performed under standard conditions in November 2015. Protein Rank metric symbol Protein name score 4F2 4F2 cell-surface antigen heavy chain 2.5000 PLOD3 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 1.4815 ELOB Transcription elongation factor B polypeptide 2 1.4350 ARPC5 Actin-related protein 2/3 complex subunit 5 1.2603 OSTF1 teoclast-stimulating factor 1 1.2500 RL5 60S ribomal protein L5 1.2135 SYK Lysine--tRNA ligase 1.2135 RL10A 60S ribomal protein L10a 1.2135 TXNL1 Thioredoxin-like protein 1 1.1716 LIS1 Platelet-activating factor acetylhydrolase IB subunit alpha 1.1067 A4 Amyloid beta A4 protein 1.0911 H2B1M Histone H2B type 1-M 1.0514 UB2V2 Ubiquitin-conjugating enzyme E2 variant 2 1.0381 PDCD5 Programmed cell death protein 5 1.0373 UCHL3 Ubiquitin carboxyl-terminal hydrolase isozyme L3 1.0061 PLEC Plectin 1.0061 ITPA Inine triphphate pyrophphatase 0.9524 IF5A1 Eukaryotic translation initiation factor 5A-1 0.9314 ARP2 Actin-related protein 2 0.8618 HNRPL Heterogeneous nuclear ribonucleoprotein L 0.8576 DNJA3 DnaJ homolog subfamily
    [Show full text]
  • Mapping of the Active Site of Glutamate Carboxypeptidase II by Site
    Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis Petra Mlcˇochova´ 1,2*, Anna Plechanovova´ 1,2*,†, Cyril Barˇinka1,‡, Daruka Mahadevan3, Jose W. Saldanha4, Lubomı´r Rulı´sˇek1 and Jan Konvalinka1,2 1 Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic 2 Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic 3 Department of Medicine, Hematology ⁄ Oncology, Arizona Cancer Center, Tucson, AZ, USA 4 National Institute for Medical Research, Division of Mathematical Biology, London, UK Keywords Human glutamate carboxypeptidase II [GCPII (EC 3.4.17.21)] is recog- active site; metallopeptidase; mutagenesis; nized as a promising pharmacological target for the treatment and imaging NAALADase; prostate specific membrane of various pathologies, including neurological disorders and prostate can- antigen cer. Recently reported crystal structures of GCPII provide structural Correspondence insight into the organization of the substrate binding cavity and highlight J. Konvalinka, Institute of Organic Chemistry residues implicated in substrate ⁄ inhibitor binding in the S1¢ site of the and Biochemistry, Academy of Sciences of enzyme. To complement and extend the structural studies, we constructed the Czech Republic, Flemingovo n. 2, a model of GCPII in complex with its substrate, N-acetyl-l-aspartyl-l-glu- 166 10 Praha 6, Czech Republic tamate, which enabled us to predict additional amino acid residues inter- Fax: +420 220 183578 acting with the bound substrate, and used site-directed mutagenesis to Tel: +420 220 183218 assess the contribution of individual residues for substrate ⁄ inhibitor bind- E-mail: [email protected] ing and enzymatic activity of GCPII.
    [Show full text]
  • Genome-Wide Profiling of Druggable Active Tumor Defense Mechanisms to Enhance Cancer Immunotherapy
    bioRxiv preprint doi: https://doi.org/10.1101/843185; this version posted November 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Genome-wide profiling of druggable active tumor defense mechanisms to enhance cancer immunotherapy Rigel J. Kishton1,2,*,#, Shashank J. Patel1,2,†,*, Suman K. Vodnala1,2, Amy E. Decker3, Yogin Patel1,2, Madhusudhanan Sukumar1,2, Tori N. Yamamoto1,2,4, Zhiya Yu1,2, Michelle Ji1,2, Amanda N. Henning1,2, Devikala Gurusamy1,2, Douglas C. Palmer1,2, Winifred Lo1, Anna Pasetto1, Parisa Malekzadeh1, Drew C. Deniger1, Kris C. Wood3, Neville E. Sanjana5,6, Nicholas P. Restifo1,2, #, § 1Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA 2Center for Cell-Based Therapy, National Cancer Institute, Bethesda, MD 20892, USA 3Department of Pharmacology & Cancer Biology, Duke University School of Medicine, Durham, NC, USA 4Immunology Graduate Group, University of Pennsylvania, Philadelphia, PA 19104, USA 5New York Genome Center, New York, NY 10013 USA 6Department of Biology, New York University, New York, NY 10003, USA *These authors contributed equally to this work. †Present address: NextCure Inc., Beltsville, MD 20705, USA §Present address: Lyell Immunopharma, South San Francisco, CA 94080, USA #Corresponding authors. NPR: [email protected]. RJK: [email protected]. bioRxiv preprint doi: https://doi.org/10.1101/843185; this version posted November 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
    [Show full text]